share_log

Private Companies Are Hunan Warrant Pharmaceutical Co.,Ltd's (SHSE:688799) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥427m Last Week

Private Companies Are Hunan Warrant Pharmaceutical Co.,Ltd's (SHSE:688799) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥427m Last Week

私营公司是湖南华纳药业有限公司, Ltd(上海证券交易所股票代码:688799)的最大所有者在上周市值上涨4.27亿元人民币后获得了回报
Simply Wall St ·  04/01 03:15

Key Insights

关键见解

  • Significant control over Hunan Warrant PharmaceuticalLtd by private companies implies that the general public has more power to influence management and governance-related decisions
  • 56% of the business is held by the top 2 shareholders
  • Insider ownership in Hunan Warrant PharmaceuticalLtd is 19%
  • 私营公司对湖南华纳德制药有限公司的重大控制意味着公众拥有更大的影响管理和治理相关决策的权力
  • 56% 的业务由前两名股东持有
  • 湖南华纳德制药有限公司的内部所有权为19%

If you want to know who really controls Hunan Warrant Pharmaceutical Co.,Ltd (SHSE:688799), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 40% to be precise, is private companies. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

如果你想知道谁真正控制了湖南华纳德制药有限公司, Ltd(上海证券交易所代码:688799),那么你必须看看其股票登记处的构成。持有该公司股份最多的集团是私营公司,准确地说约为40%。也就是说,如果股票上涨,该集团将受益最大(如果股价下跌,则损失最大)。

As a result, private companies were the biggest beneficiaries of last week's 9.7% gain.

结果,私营公司是上周9.7%涨幅的最大受益者。

In the chart below, we zoom in on the different ownership groups of Hunan Warrant PharmaceuticalLtd.

在下图中,我们放大了湖南华纳德制药有限公司的不同所有权组。

ownership-breakdown
SHSE:688799 Ownership Breakdown April 1st 2024
SHSE: 688799 所有权明细 2024 年 4 月 1 日

What Does The Institutional Ownership Tell Us About Hunan Warrant PharmaceuticalLtd?

关于湖南华纳德制药有限公司,机构所有权告诉我们什么?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

机构在向自己的投资者报告时通常会根据基准来衡量自己,因此,一旦股票被纳入主要指数,他们通常会对股票更加热情。我们预计大多数公司都会有一些机构在册,尤其是在它们正在成长的情况下。

As you can see, institutional investors have a fair amount of stake in Hunan Warrant PharmaceuticalLtd. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Hunan Warrant PharmaceuticalLtd, (below). Of course, keep in mind that there are other factors to consider, too.

如你所见,机构投资者持有湖南华纳德制药有限公司的相当数量的股份。这可能表明该公司在投资界具有一定程度的信誉。但是,最好谨慎行事,不要依赖机构投资者所谓的验证。他们也是,有时候会弄错。如果两个大型机构投资者试图同时抛售股票,股价大幅下跌的情况并不少见。因此,值得查看湖南华纳德制药有限公司过去的收益轨迹(见下文)。当然,请记住,还有其他因素需要考虑。

earnings-and-revenue-growth
SHSE:688799 Earnings and Revenue Growth April 1st 2024
SHSE: 688799 2024 年 4 月 1 日收益和收入增长

We note that hedge funds don't have a meaningful investment in Hunan Warrant PharmaceuticalLtd. Our data shows that Hunan Warrant Pharmaceutical Investment Partnership Enterprise (Limited Partnership) is the largest shareholder with 40% of shares outstanding. For context, the second largest shareholder holds about 17% of the shares outstanding, followed by an ownership of 2.5% by the third-largest shareholder. Yan Jin, who is the third-largest shareholder, also happens to hold the title of Chairman of Corporate Board.

我们注意到,对冲基金没有对湖南华纳德制药有限公司进行有意义的投资。我们的数据显示,湖南华纳德医药投资合伙企业(有限合伙)是最大股东,已发行股份的40%。就背景而言,第二大股东持有约17%的已发行股份,其次是第三大股东持有2.5%的所有权。第三大股东严进也恰好拥有公司董事会主席的头衔。

To make our study more interesting, we found that the top 2 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company.

为了使我们的研究更有趣,我们发现前两名股东拥有公司的多数股权,这意味着他们足够强大,足以影响公司的决策。

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There is some analyst coverage of the stock, but it could still become more well known, with time.

虽然研究公司的机构所有权可以为您的研究增加价值,但研究分析师的建议以更深入地了解股票的预期表现也是一种好做法。有一些分析师对这只股票的报道,但随着时间的推移,它仍可能变得更加广为人知。

Insider Ownership Of Hunan Warrant PharmaceuticalLtd

湖南华纳德制药有限公司的内部所有权

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

公司内部人员的定义可能是主观的,并且在不同的司法管辖区之间确实有所不同。我们的数据反映了个人内部人士,至少涵盖了董事会成员。管理层最终对董事会负责。但是,经理成为执行委员会成员的情况并不少见,尤其是当他们是创始人或首席执行官时。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多数人认为内部所有权是积极的,因为这可能表明董事会与其他股东关系良好。但是,在某些情况下,过多的权力集中在该群体中。

Our information suggests that insiders maintain a significant holding in Hunan Warrant Pharmaceutical Co.,Ltd. Insiders own CN¥927m worth of shares in the CN¥4.8b company. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling.

我们的信息表明,内部人士持有湖南华纳德制药有限公司的大量股份。, Ltd. 内部人士拥有这家48亿元人民币公司价值9.27亿元人民币的股份。这可能表明创始人仍然拥有大量股份。你可以点击这里查看他们是否在买入或卖出。

General Public Ownership

一般公有制

With a 30% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Hunan Warrant PharmaceuticalLtd. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

拥有30%所有权的公众,主要由个人投资者组成,对湖南华德制药有限公司有一定程度的影响力。这种所有权规模虽然可观,但如果决策与其他大股东不同步,可能不足以改变公司政策。

Private Company Ownership

私人公司所有权

It seems that Private Companies own 40%, of the Hunan Warrant PharmaceuticalLtd stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

私人公司似乎拥有湖南沃瑞德制药有限公司40%的股份。私营公司可能是关联方。有时,内部人士通过控股私营公司而对上市公司拥有权益,而不是以个人身份拥有权益。尽管很难得出任何宽泛的结论,但值得注意的是,这是一个需要进一步研究的领域。

Next Steps:

后续步骤:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For example, we've discovered 1 warning sign for Hunan Warrant PharmaceuticalLtd that you should be aware of before investing here.

我觉得看看究竟谁拥有一家公司非常有趣。但是,要真正获得见解,我们还需要考虑其他信息。例如,我们发现了湖南华瑞德制药有限公司的一个警告信号,在这里投资之前,你应该注意这个信号。

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

如果你像我一样,你可能需要考虑这家公司是会成长还是会萎缩。幸运的是,您可以查看这份免费报告,其中显示了分析师对其未来的预测。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后一天的12个月期间。这可能与全年年度报告数据不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发